Coronavirus vaccine

US12133899B2 · kind B2 · utility

Assignee

• BIONTECH SE · DE

Inventors

• Ugur Sahin · Mainz, DE
• Alptekin Güler · Mainz, DE
• Andreas Kuhn · Mainz, DE
• Alexander Muik · Seeheim-Jugenheim, DE
• Annette Vogel · Mainz, DE
• Kerstin Walzer · Seeheim-Jugenheim, DE
• Sonja Witzel · Bad Vilbel, DE
• Stephanie Hein · Rüsselsheim am Main, DE
• Ozlem Tureci · Homburg, DE

Key dates

• Filing date: Nov 16, 2022
• Grant date: Nov 5, 2024
• Expiry date: Nov 16, 2042

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.